Business Description
Zelira Therapeutics Ltd
SIC : 2833
ISIN : AU000000ZLD1
Total Employee Number:
8Description
Zelira Therapeutics Ltd is an Australian biotechnology company that develops and commercializes cannabinoid-based medicines for a range of medical conditions. Its product portfolio includes proprietary formulations such as HOPE, Zenivol and Dalirex, targeting areas including insomnia, chronic pain, autism, eczema and other neurological and inflammatory conditions. The company advances these assets through clinical and preclinical research programs, and also sells medicinal cannabis products in Australia through prescription channels. Zelira operates across two geographic segments, Australia and the United States, where it has pursued partnerships and licensing arrangements to commercialize its formulations in the US market. Revenue is generated primarily from product sales of its medicinal cannabis formulations and from licensing and collaboration agreements with partners. The company is headquartered in Perth, Western Australia, and its shares are listed on the Australian Securities Exchange.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Equity-to-Asset | -3.43 | |||||
Debt-to-Equity | -0.48 | |||||
Debt-to-EBITDA | -0.68 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | -104.11 | |||||
Beneish M-Score | 13.21 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 42.7 | |||||
3-Year EPS without NRI Growth Rate | 45.7 | |||||
3-Year FCF Growth Rate | 28.6 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 33.3 | |||||
9-Day RSI | 38.55 | |||||
14-Day RSI | 43.73 | |||||
12-1 Month Momentum % | 30.43 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.11 | |||||
Quick Ratio | 0.02 | |||||
Days Inventory | 41407.22 | |||||
Days Sales Outstanding | 26280 | |||||
Days Payable | 147595.19 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -7.5 | |||||
Shareholder Yield % | -6.44 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | -800 | |||||
Operating Margin % | -380900 | |||||
Net Margin % | -362800 | |||||
EBITDA Margin % | -317200 | |||||
FCF Margin % | -711539.29 | |||||
OCF Margin % | -711541.37 | |||||
ROA % | -122.72 | |||||
ROIC % | -78.96 | |||||
3-Year ROIIC % | -32.13 | |||||
ROC (Joel Greenblatt) % | -1665.97 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
EV-to-EBIT | -2.4 | |||||
EV-to-EBITDA | -2.6 | |||||
EV-to-Revenue | 8254 | |||||
EV-to-FCF | -1.68 | |||||
Price-to-GF-Value | 4.29 | |||||
Earnings Yield (Greenblatt) % | -41.67 | |||||
FCF Yield % | -82.48 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Zelira Therapeutics Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -0.19 | ||
| Beta | 3.2959 | ||
| 3-Year Sharpe Ratio | 0.07 | ||
| 3-Year Sortino Ratio | 0.14 | ||
| Volatility % | 69.36 | ||
| 14-Day RSI | 43.73 | ||
| 14-Day ATR (€) | 0.017422 | ||
| 20-Day SMA (€) | 0.3386 | ||
| 12-1 Month Momentum % | 30.43 | ||
| 52-Week Range (€) | 0.167 - 0.51 | ||
| Shares Outstanding (Mil) | 13.15 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Zelira Therapeutics Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Zelira Therapeutics Ltd Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| 0.005714:1 Stock Split | 2022-04-14 | 1.58 (+0.00%) | ||
| 0.2:1 Stock Split | 2016-10-17 | -- | ||
| 0.2:1 Stock Split | 2008-03-06 | -- |
Show
Entries
Zelira Therapeutics Ltd Frequently Asked Questions
What is Zelira Therapeutics Ltd(FRA:G1G)'s stock price today?
The current price of FRA:G1G is €0.30. The 52 week high of FRA:G1G is €0.51 and 52 week low is €0.17.
When is next earnings date of Zelira Therapeutics Ltd(FRA:G1G)?
The next earnings date of Zelira Therapeutics Ltd(FRA:G1G) is .
Does Zelira Therapeutics Ltd(FRA:G1G) pay dividends? If so, how much?
Zelira Therapeutics Ltd(FRA:G1G) does not pay dividend.
Press Release
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers